Centre Testing Intl Shenzhen (300012) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Centre Testing Intl Shenzhen stock ¥16.97, price ¥15.71, upside +8.0%, quality 65 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 2, 2026.
How to read this chart
60‑month range ¥9.30 – ¥33.83 · fair‑value band ¥10.86 – ¥25.86 · the ¥15.71 price screens below the ¥16.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 2, 2026.
Follow Centre Testing Intl Shenzhen in your weekly email
Every Wednesday you see whether Centre Testing Intl Shenzhen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Centre Testing International Group Co. Ltd. provides testing, inspection, certification, calibration, audit, training, and technical services in China and internationally.
Show moreShow less
It operates in five segments: Trade Protection; Consumer Product Testing; Industrial Testing; Life Sciences; and Pharmaceuticals and Medical Services.
The company offers environmental protection and regulatory; in-vehicle electronics; vehicle and parts; connectors and fasteners; rail transit; hazardous substances in vessel; aviation materials; special equipment; toys; home supplies; furniture and furniture materials; food contact material; table and kitchenware; medical device; electromagnetic compatibility; safety compliance; reliability; green/ environmental protection; construction works; combustion performance; foundation and on-site physical inspection; construction site monitory/measurement; building material testing; CTI sets; food and product type inspection; pet food and feed; agricultural materials; health food and FSMP; industry quality control plans; footwear/bags, textile, and garment testing; lubricant oil condition monitoring; petroleum products; fuel oil; chemical product and green environmental testing; metal material; polymer materials; food contact material; occupational and public health; and environmental monitoring services.
It also provides CE, system, service, and product certification services; food safety; electronic and electrical appliances; building materials, rail, transit, and industrial equipment and manufacturing services; and consumer product inspection, wind power equipment manufacturing supervision, wind turbine and industrial product inspection, non-destructive and foundation-based testing, engineering on-site monitoring and measurement, luxury goods inspection, pest control, bulk commodity inspection, and government-entrusted inspection services.
Centre Testing International Group Co. Ltd. was incorporated in 2003 and is headquartered in Shenzhen, China.
Stock analysis
Centre Testing Intl Shenzhen (300012) currently trades at ¥15.71, while our model-based Fair Value estimate is ¥16.97, so the stock looks roughly fairly valued today (gap 7.4%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥16.39 per share, and 7 of the 26 models we run sit above the ¥15.71 price.
Bear case: the Dividend Discount group reads lowest at ¥2.24, and 19 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥10.86 (bear) to ¥25.86 (bull), the price of ¥15.71 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Industrials sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Centre Testing Intl Shenzhen reported revenue of 6.6B CNY in FY2025 versus 4.3B CNY in FY2021, a compound +11.2%/yr. Reported net income was 1.0B CNY in FY2025, compounding +8.0%/yr from FY2021.
Key figures
Market cap 26.4B CNY (≈ $4.0B) Mid · P/E ratio 22.8 · P/S ratio 3.60 · EPS (TTM) ¥0.6900 · Dividend yield 1.6% · Net margin 15.9% · Return on equity 14.4% · Return on assets (EBIT) 11.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 67 out of 100 (low confidence).
What moves the price
The share trades about 8% below its 52-week high and 21% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −15% fair-value upside, at 8%, 300012 screens cheaper than that median.
Fair Value models
Bear¥10.86Fair Value ¥16.97Bull¥25.86
Price ¥15.71 · Upside +8.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.3761 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.98/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+8.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.2%
Start year 2020 (pandemic). Over 10 years: +17.8% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+13.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.9%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.9% vs 20.0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 17%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+21.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+11.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +19.5% a year for the price and +9.9% for the forecasts.
Compare Centre Testing Intl Shenzhen with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 230 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score65 · Top 25%
Fair Value upside+8.0% · Above median
Profitability
Return on equity (12 months)14.4% · Above median
Return on assets9.8% · Top 25%
Net margin (12 months)15.9% · Top 25%
Operating margin (12 months)22.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)14.3% · Above median
Dividend yield (12 months)1.6% · Below median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Specialty Business Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Centre Testing Intl Shenzhen (300012) overvalued or undervalued?
As of Nov 2, 2026, our model estimates a fair value of ¥16.97 versus a price of ¥15.71, about +8% upside (fairly valued).
What is the fair value of 300012?
Our model-based fair value for Centre Testing Intl Shenzhen is ¥16.97 (as of Nov 2, 2026), built from audited fundamentals. The current price: ¥15.71.
What is the quality score of 300012?
Centre Testing Intl Shenzhen has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Centre Testing Intl Shenzhen (300012)?
Our model-based price target is the fair value of ¥16.97 (as of Nov 2, 2026) from 26 valuation models. Cautious scenario ¥10.86, optimistic scenario ¥25.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Centre Testing Intl Shenzhen stock forecast for 2026?
Our models put fair value at ¥16.97, about +8% upside versus a price of ¥15.71 (fairly valued). Cautious scenario ¥10.86, optimistic scenario ¥25.86. The calculation is refreshed regularly with new filings.
What is the revenue of Centre Testing Intl Shenzhen (300012)?
Centre Testing Intl Shenzhen reported trailing-twelve-month revenue of about 7.3B CNY (latest available figure, as of Nov 2, 2026).
Does Centre Testing Intl Shenzhen pay a dividend?
Centre Testing Intl Shenzhen currently shows a dividend yield of 1.59% relative to its recent price (as of Nov 2, 2026).
How much is the dividend of Centre Testing Intl Shenzhen (300012) and when is the ex-dividend date?
Centre Testing Intl Shenzhen pays a dividend of ¥0.25 per share a year, a dividend yield of 1.6%. The last ex-dividend date was Aug 26, 2026. A dividend has been paid every year since at least 2010. The payout ratio is 36.2% of earnings. Free cash flow covers the dividend 1.69 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Centre Testing Intl Shenzhen (300012)?
For today's price to be fair in a discounted-cash-flow model, Centre Testing Intl Shenzhen would have to grow free cash flow by +21.5 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.2 % per year. As of Nov 2, 2026.
What discount rate (WACC) does the fair value of 300012 use?
Our models discount Centre Testing Intl Shenzhen at 10.2 %: a base by market capitalisation (mid), damped by beta 0.91, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Centre Testing Intl Shenzhen that is +21.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has Centre Testing Intl Shenzhen (300012) delivered so far?
Over the past 5 years revenue at Centre Testing Intl Shenzhen grew +13.2 % a year. The price currently implies free-cash-flow growth of +21.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Centre Testing Intl Shenzhen (300012) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Centre Testing Intl Shenzhen (+21.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Centre Testing Intl Shenzhen (300012)?
The free-cash-flow yield on the price is 2.70 %: that much free cash flow Centre Testing Intl Shenzhen produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Centre Testing Intl Shenzhen (300012)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Centre Testing Intl Shenzhen it is ¥16.97 per share (as of Nov 2, 2026), against a price of ¥15.71. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Centre Testing Intl Shenzhen stock overvalued or undervalued in 2026?
As of Nov 2, 2026, 300012 trades below its calculated fair value: price ¥15.71, fair value ¥16.97, a gap of about +8% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300012?
No. The price is what the market pays today (¥15.71); the fair value is what the company's own numbers justify (¥16.97). For Centre Testing Intl Shenzhen the two are ¥1.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Centre Testing Intl Shenzhen worth?
The market values Centre Testing Intl Shenzhen at about 26.4B CNY (market capitalisation, as of Nov 2, 2026). Per share that is ¥15.71; our models calculate a fair value of ¥16.97 per share.
What do the bullish and bearish scenarios say about 300012?
Our models span a range for Centre Testing Intl Shenzhen: cautious scenario ¥10.86, base ¥16.97, optimistic ¥25.86 per share (as of Nov 2, 2026, price ¥15.71). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300012?
Centre Testing Intl Shenzhen trades at a price-to-earnings ratio of 22.8 (as of Nov 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.97 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2017 to 2025), reported earnings: 41.5. Other multiples: P/B 3.5, P/S 3.6, EV/EBITDA 16.4.
How solid is the balance sheet of Centre Testing Intl Shenzhen (300012)?
Balance-sheet figures for Centre Testing Intl Shenzhen (as of Nov 2, 2026): return on equity 14.4%, debt of 0.00 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is 300012 from its 52-week high?
Centre Testing Intl Shenzhen trades at ¥15.71, about 8% below its 52-week high of ¥17.12 and 21% above the low of ¥13.04 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.97 is for.
Which stocks are comparable to Centre Testing Intl Shenzhen?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Centre Testing Intl Shenzhen stock attractive at the current price?
The data as of Nov 2, 2026: price ¥15.71, calculated fair value ¥16.97 (+8%), Quality Score 65/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300012 calculated?
We run Centre Testing Intl Shenzhen through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥16.97 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Centre Testing Intl Shenzhen currently trades 7% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Centre Testing Intl Shenzhen (300012)?
The closing price on Nov 6, 2026 was ¥15.71. Our model-based fair value is ¥16.97, about +8% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Centre Testing Intl Shenzhen right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (¥10.86 to ¥25.86) leaves room in how you read the outcome.
Where does the earnings growth of Centre Testing Intl Shenzhen (300012) come from?
Earnings per share at Centre Testing Intl Shenzhen grew +20.0 % a year from 2013 to 2024. Broken into its drivers: revenue per share +19.7 %, EBIT margin +0.3 %, tax rate +1.0 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Centre Testing Intl Shenzhen
How large is the market capitalisation of Centre Testing Intl Shenzhen (300012)?
The market capitalisation of Centre Testing Intl Shenzhen is 26.4B CNY (≈ $4.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Centre Testing Intl Shenzhen (300012)?
The price-to-sales ratio of Centre Testing Intl Shenzhen is 3.60 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Centre Testing Intl Shenzhen (300012)?
Earnings per share at Centre Testing Intl Shenzhen are ¥0.6900 (price ÷ EPS = P/E 22.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Centre Testing Intl Shenzhen (300012)?
The dividend yield of Centre Testing Intl Shenzhen is 1.6% (payout 36.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Centre Testing Intl Shenzhen (300012)?
The net margin of Centre Testing Intl Shenzhen is 15.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Centre Testing Intl Shenzhen (300012)?
The return on equity (ROE) of Centre Testing Intl Shenzhen is 14.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Centre Testing Intl Shenzhen (300012)?
On an EBIT basis the return on assets of Centre Testing Intl Shenzhen is 11.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Centre Testing Intl Shenzhen (300012)?
The operating margin of Centre Testing Intl Shenzhen is 22.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Centre Testing Intl Shenzhen (300012)?
Revenue at Centre Testing Intl Shenzhen is growing +14.3% versus a year earlier (3y avg +8.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Centre Testing Intl Shenzhen (300012)?
Earnings per share at Centre Testing Intl Shenzhen are growing +13.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Centre Testing Intl Shenzhen (300012) hold?
Centre Testing Intl Shenzhen holds more cash than debt, 640M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Centre Testing Intl Shenzhen in the live analysis
One click puts Centre Testing Intl Shenzhen on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 2, 2026